Sales 15,035 $ 14,593 $ 3% 29,522 $ 30,494 $ -3% Costs, Expenses and Other Cost of sales 4,024 4,216 -5% 7,951 9,596 -17% Selling, general and administrative 2,702 2,512 8% 5,182 4,834 7% Research and development 13,321 2,798 * 17,597 5,374 * Restructuring costs 151 142 6% 218 194 12% Other (income) expense, net 172 438 -61% 259 1,148 -77% (Loss) Income Before Taxes (5,335) 4,487 * (1,685) 9,348 * Income Tax Provision 637 538 1,462 1,092 Net (Loss) Income (5,972) 3,949 * (3,147) 8,256 * Less: Net Income Attributable to Noncontrolling Interests 3 5 7 2 Net (Loss) Income Attributable to Merck & Co., Inc. (5,975) $ 3,944 $ * (3,154) $ 8,254 $ * (Loss) Earnings per Common Share Assuming Dilution (1) (2.35) $ 1.55 $ * (1.24) $ 3.25 $ * Average Shares Outstanding Assuming Dilution (1) 2,539 2,540 2,539 2,538 Tax Rate -11.9% 12.0% -86.8% 11.7% * 100% or greater (1) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 2Q23 2Q22 June YTD 2023 June YTD 2022 -- 1 of 9 -- Sales 14,487 $ 15,035 $ 29,522 $ 15,901 $ 14,593 $ 30,494 $ 14,959 $ 13,830 $ 59,283 $ 3% -3% Costs, Expenses and Other Cost of sales 3,926 4,024 7,951 5,380 4,216 9,596 3,934 3,881 17,411 -5% -17% Selling, general and administrative 2,479 2,702 5,182 2,323 2,512 4,834 2,520 2,687 10,042 8% 7% Research and development 4,276 13,321 17,597 2,576 2,798 5,374 4,399 3,775 13,548 * * Restructuring costs 67 151 218 53 142 194 94 49 337 6% 12% Other (income) expense, net 89 172 259 708 438 1,148 429 (75) 1,501 -61% -77% Income (Loss) Before Taxes 3,650 (5,335) (1,685) 4,861 4,487 9,348 3,583 3,513 16,444 * * Income Tax Provision 825 637 1,462 554 538 1,092 330 495 1,918 Net Income (Loss) 2,825 (5,972) (3,147) 4,307 3,949 8,256 3,253 3,018 14,526 * * Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 3 7 (3) 5 2 5 1 7 Net Income (Loss) Attributable to Merck & Co., Inc. 2,821 $ (5,975) $ (3,154) $ 4,310 $ 3,944 $ 8,254 $ 3,248 $ 3,017 $ 14,519 $ * * Earnings (Loss) per Common Share Assuming Dilution (1) 1.11 $ (2.35) $ (1.24) $ 1.70 $ 1.55 $ 3.25 $ 1.28 $ 1.18 $ 5.71 $ * * Average Shares Outstanding Assuming Dilution (1) 2,551 2,539 2,539 2,537 2,540 2,538 2,542 2,548 2,542 Tax Rate from Continuing Operations 22.6% -11.9% -86.8% 11.4% 12.0% 11.7% 9.2% 14.1% 11.7% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 2Q June YTD June YTD 2023 2Q June YTD 1Q 1Q 2Q 3Q 4Q Full Year 2022 Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) -- 2 of 9 -- Second Quarter Cost of sales 4,024 $ 467 32 499 3,525 $ Selling, general and administrative 2,702 25 52 77 2,625 Research and development 13,321 9 1 10 13,311 Restructuring costs 151 151 151 - Other (income) expense, net 172 (3) 194 191 (19) Loss Before Taxes (5,335) (498) (236) (194) (928) (4,407) Income Tax Provision (Benefit) 637 (91) (4) (38) (4) (44) (4) (173) 810 Net Loss (5,972) (407) (198) (150) (755) (5,217) Net Loss Attributable to Merck & Co., Inc. (5,975) (407) (198) (150) (755) (5,220) Loss per Common Share Assuming Dilution (5) (2.35) $ (0.16) (0.07) (0.06) (0.29) (2.06) $ Tax Rate -11.9% -18.4% June YTD Cost of sales 7,951 $ 1,012 61 1,073 6,878 $ Selling, general and administrative 5,182 45 53 98 5,084 Research and development 17,597 19 1 20 17,577 Restructuring costs 218 218 218 - Other (income) expense, net 259 12 (235) 573 (3) 350 (91) (Loss) Income Before Taxes (1,685) (1,088) (333) 235 (573) (1,759) 74 Income Tax Provision (Benefit) 1,462 (196) (4) (56) (4) 51 (4) (60) (4) (261) 1,723 Net Loss (3,147) (892) (277) 184 (513) (1,498) (1,649) Net Loss Attributable to Merck & Co., Inc. (3,154) (892) (277) 184 (513) (1,498) (1,656) Loss per Common Share Assuming Dilution (5) (1.24) $ (0.35) (0.11) 0.07 (0.20) (0.59) (0.65) $ Tax Rate -86.8% 2,328.4% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the six-month period primarily reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (5) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THREE AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a Certain Other Items -- 3 of 9 -- Second Quarter Cost of sales 4,216 $ 451 67 518 3,698 $ Selling, general and administrative 2,512 65 27 92 2,420 Research and development 2,798 12 22 34 2,764 Restructuring costs 142 142 142 - Other (income) expense, net 438 2 234 236 202 Income Before Taxes 4,487 (530) (258) (234) (1,022) 5,509 Income Tax Provision (Benefit) 538 (131) (3) (40) (3) (52) (3) (223) 761 Net Income 3,949 (399) (218) (182) (799) 4,748 Net Income Attributable to Merck & Co., Inc. 3,944 (399) (218) (182) (799) 4,743 Earnings per Common Share Assuming Dilution 1.55 $ (0.16) (0.09) (0.07) (0.32) 1.87 $ Tax Rate 12.0% 13.8% June YTD Cost of sales 9,596 $ 1,131 113 1,244 8,352 $ Selling, general and administrative 4,834 115 48 163 4,671 Research and development 5,374 34 29 63 5,311 Restructuring costs 194 - 194 194 - Other (income) expense, net 1,148 (112) 918 806 342 Income Before Taxes 9,348 (1,168) (384) (918) (2,470) 11,818 Income Tax Provision (Benefit) 1,092 (286) (3) (62) (3) (204) (3) (552) 1,644 Net Income 8,256 (882) (322) (714) (1,918) 10,174 Net Income Attributable to Merck & Co., Inc. 8,254 (882) (322) (714) (1,918) 10,172 Earnings per Common Share Assuming Dilution 3.25 $ (0.35) (0.13) (0.28) (0.76) 4.01 $ Tax Rate 11.7% 13.9% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. THREE AND SIX MONTHS ENDED JUNE 30, 2022 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the six-month period primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal -- 4 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2023 2022 2Q June YTD 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $14,487 $15,035 $29,522 $15,901 $14,593 $30,494 $14,959 $13,830 $59,283 3 7 -3 - PHARMACEUTICAL 12,721 13,457 26,179 14,107 12,756 26,863 12,963 12,180 52,005 6 8 -3 - Oncology Keytruda 5,795 6,271 12,065 4,809 5,252 10,061 5,426 5,450 20,937 19 21 20 23 Alliance Revenue – Lynparza (2) 275 310 585 266 275 541 284 292 1,116 13 15 8 12 Alliance Revenue – Lenvima (2) 232 242 474 227 231 459 202 216 876 5 6 3 5 Welireg 42 50 92 18 27 45 38 40 123 89 89 105 105 Alliance Revenue – Reblozyl (3) 43 47 90 52 33 86 39 41 166 41 41 4 4 Vaccines (4) Gardasil / Gardasil 9 1,972 2,458 4,430 1,460 1,674 3,133 2,294 1,470 6,897 47 53 41 48 ProQuad / M-M-R II / Varivax 528 582 1,109 470 578 1,047 668 526 2,241 1 1 6 7 RotaTeq 297 131 428 216 173 389 256 139 783 -25 -24 10 13 Vaxneuvance 106 168 274 5 12 16 16 138 170 * * * * Pneumovax 23 96 92 188 173 153 325 131 145 602 -40 -38 -42 -39 Vaqta 40 42 82 36 35 71 64 39 173 20 20 16 17 Hospital Acute Care Bridion 487 502 989 395 426 821 423 441 1,685 18 19 21 23 Prevymis 129 143 273 94 103 197 114 118 428 39 42 39 43 Dificid 65 76 141 52 66 119 77 67 263 14 14 19 19 Primaxin 80 53 133 58 64 122 63 54 239 -16 -12 9 17 Noxafil 60 55 116 57 60 118 62 58 238 -8 -3 -2 5 Zerbaxa 50 54 104 30 46 76 43 49 169 17 18 36 39 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 99 68 167 72 98 170 88 82 341 -31 -31 -2 -2 Adempas (6) 59 65 125 61 63 124 57 57 238 3 5 - 5 Virology Lagevrio 392 203 595 3,247 1,177 4,424 436 825 5,684 -83 -82 -87 -85 Isentress / Isentress HD 123 136 259 158 147 305 161 167 633 -7 -4 -15 -12 Neuroscience Belsomra 56 63 119 69 69 137 62 59 258 -9 -4 -14 -7 Immunology Simponi 180 180 359 186 181 366 173 166 706 -1 -1 -2 1 Remicade 51 48 99 61 53 114 49 44 207 -11 -10 -13 -10 Diabetes (7) Januvia 551 511 1,062 779 756 1,535 717 561 2,813 -33 -30 -31 -28 Janumet 329 354 683 454 476 931 417 353 1,700 -26 -23 -27 -24 Other Pharmaceutical (8) 584 553 1,138 602 528 1,131 603 583 2,319 5 8 1 4 ANIMAL HEALTH 1,491 1,456 2,947 1,482 1,467 2,949 1,371 1,230 5,550 -1 2 - 4 Livestock 849 807 1,656 832 826 1,658 829 814 3,300 -2 2 - 5 Companion Animal 642 649 1,291 650 641 1,291 542 416 2,250 1 2 - 2 Other Revenues (9) 275 122 396 312 370 682 625 420 1,728 -67 -19 -42 -20 *200% or greater (7) Total Diabetes sales were $950 million and $951 million in the first and second quarter of 2023, respectively, and $1,305 million and $1,300 million in the first and second quarter of 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million and $3 million in the first and second quarter of 2023, respectively, and $114 million and $32 million in the first and second quarter of 2022, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $3,133 million and $3,557 million in the first and second quarter of 2023, respectively, and $2,481 million and $2,709 million in the first and second quarter of 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. -- 5 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES SECOND QUARTER 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 2Q 2023 2Q 2022 % Change 2Q 2023 2Q 2022 % Change 2Q 2023 2Q 2022 % Change TOTAL SALES (1) $15,035 $14,593 3 $7,018 $6,238 12 $8,018 $8,355 -4 PHARMACEUTICAL 13,457 12,756 6 6,570 5,726 15 6,887 7,030 -2 Oncology Keytruda 6,271 5,252 19 3,863 3,197 21 2,408 2,055 17 Alliance Revenue – Lynparza (2) 310 275 13 144 143 1 166 132 26 Alliance Revenue – Lenvima (2) 242 231 5 163 128 28 79 103 -24 Welireg 50 27 89 49 27 84 2 * Alliance Revenue – Reblozyl 47 33 41 36 28 26 11 5 123 Vaccines (3) Gardasil / Gardasil 9 2,458 1,674 47 464 428 8 1,994 1,245 60 ProQuad / M-M-R II / Varivax 582 578 1 447 434 3 135 143 -6 Vaxneuvance 168 12 * 147 11 * 20 * RotaTeq 131 173 -25 93 98 -5 37 75 -50 Pneumovax 23 92 153 -40 23 94 -76 69 59 17 Vaqta 42 35 20 29 16 76 13 19 -29 Hospital Acute Care Bridion 502 426 18 299 237 27 203 190 7 Prevymis 143 103 39 61 47 31 82 56 46 Dificid 76 66 14 68 63 8 8 3 144 Noxafil 55 60 -8 11 16 -32 45 45 - Zerbaxa 54 46 17 30 22 36 24 24 -1 Primaxin 53 64 -16 -2 * 56 64 -13 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 68 98 -31 70 88 -21 -2 10 -119 Adempas (5) 65 63 3 65 63 3 Virology Lagevrio 203 1,177 -83 2 * 201 1,177 -83 Isentress / Isentress HD 136 147 -7 56 67 -16 80 80 1 Neuroscience Belsomra 63 69 -9 21 19 10 42 50 -16 Immunology Simponi 180 181 -1 180 181 -1 Remicade 48 53 -11 48 53 -11 Diabetes (6) Januvia 511 756 -33 243 301 -19 267 455 -41 Janumet 354 476 -26 82 105 -22 272 371 -27 Other Pharmaceutical (7) 553 528 5 171 157 9 382 372 3 ANIMAL HEALTH 1,456 1,467 -1 475 477 -1 982 990 -1 Livestock 807 826 -2 165 164 1 643 662 -3 Companion Animal 649 641 1 310 313 -1 339 328 4 Other Revenues (8) 122 370 -67 -27 35 -177 149 335 -56 *200% or greater (6) Total Diabetes sales were $951 million in the second quarter of 2023 and $1,300 million in the second quarter of 2022. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $3 million in the second quarter of 2023 and $32 million in the second quarter of 2022. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $3,557 million in the second quarter of 2023 and $2,709 million in the second quarter of 2022. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. -- 6 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES JUNE YEAR-TO-DATE 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International June YTD 2023 June YTD 2022 % Change June YTD 2023 June YTD 2022 % Change June YTD 2023 June YTD 2022 % Change TOTAL SALES (1) $29,522 $30,494 -3 $13,676 $13,577 1 $15,846 $16,917 -6 PHARMACEUTICAL 26,179 26,863 -3 12,688 12,498 2 13,491 14,364 -6 Oncology Keytruda 12,065 10,061 20 7,348 5,976 23 4,718 4,085 15 Alliance Revenue – Lynparza (2) 585 541 8 286 283 1 299 257 16 Alliance Revenue – Lenvima (2) 474 459 3 316 284 11 158 175 -10 Welireg 92 45 105 90 45 99 3 * Alliance Revenue – Reblozyl (3) 90 86 4 66 55 19 24 30 -22 Vaccines (4) Gardasil / Gardasil 9 4,430 3,133 41 880 846 4 3,550 2,287 55 ProQuad / M-M-R II / Varivax 1,109 1,047 6 868 805 8 242 243 - RotaTeq 428 389 10 273 273 - 155 116 34 Vaxneuvance 274 16 * 241 16 * 33 1 * Pneumovax 23 188 325 -42 63 212 -70 125 114 10 Vaqta 82 71 16 59 45 30 23 25 -8 Hospital Acute Care Bridion 989 821 21 576 432 33 413 389 6 Prevymis 273 197 39 116 87 34 157 110 43 Dificid 141 119 19 130 113 15 11 6 80 Primaxin 133 122 9 2 1 128 132 122 8 Noxafil 116 118 -2 25 25 -2 91 92 -2 Zerbaxa 104 76 36 57 40 42 47 36 29 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 167 170 -2 153 159 -4 14 11 24 Adempas (6) 125 124 - 125 124 - Virology Lagevrio 595 4,424 -87 1,523 -100 595 2,901 -79 Isentress / Isentress HD 259 305 -15 108 128 -16 151 177 -15 Neuroscience Belsomra 119 137 -14 37 39 -6 82 98 -17 Immunology Simponi 359 366 -2 359 366 -2 Remicade 99 114 -13 99 114 -13 Diabetes (7) Januvia 1,062 1,535 -31 514 626 -18 548 909 -40 Janumet 683 931 -27 138 168 -18 544 762 -29 Other Pharmaceutical (8) 1,138 1,131 1 342 317 8 793 814 -3 ANIMAL HEALTH 2,947 2,949 - 956 951 1 1,991 1,998 - Livestock 1,656 1,658 - 338 335 1 1,318 1,322 - Companion Animal 1,291 1,291 - 618 616 - 673 676 - Other Revenues (9) 396 682 -42 32 128 -75 364 555 -34 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,901 million and $2,605 million on a global share basis for June YTD 2023 and 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $54 million and $146 million on a global share basis for June YTD 2023 and 2022, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $6,690 million and $5,191 million on a global share basis for June YTD 2023 and 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. -- 7 of 9 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2023 2022 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD TOTAL PHARMACEUTICAL $12,721 $13,457 $26,179 $14,107 $12,756 $26,863 $12,963 $12,180 $52,005 6 -3 United States 6,117 6,570 12,688 6,773 5,726 12,499 6,620 5,871 24,989 15 2 % Pharmaceutical Sales 48.1% 48.8% 48.5% 48.0% 44.9% 46.5% 51.1% 48.2% 48.1% Europe (1) 2,326 2,401 4,727 3,309 2,677 5,986 2,427 2,494 10,906 -10 -21 % Pharmaceutical Sales 18.3% 17.8% 18.1% 23.5% 21.0% 22.3% 18.7% 20.5% 21.0% China 1,694 1,887 3,581 1,113 1,355 2,468 1,419 1,216 5,102 39 45 % Pharmaceutical Sales 13.3% 14.0% 13.7% 7.9% 10.6% 9.2% 10.9% 10.0% 9.8% Asia Pacific (other than China and Japan) 703 705 1,409 786 854 1,640 702 691 3,034 -17 -14 % Pharmaceutical Sales 5.5% 5.2% 5.4% 5.6% 6.7% 6.1% 5.4% 5.7% 5.8% Japan 737 652 1,390 965 1,092 2,057 653 832 3,542 -40 -32 % Pharmaceutical Sales 5.8% 4.8% 5.3% 6.8% 8.6% 7.7% 5.0% 6.8% 6.8% Latin America 470 566 1,036 435 453 888 511 472 1,871 25 17 % Pharmaceutical Sales 3.7% 4.2% 4.0% 3.1% 3.6% 3.3% 3.9% 3.9% 3.6% Eastern Europe/Middle East/Africa 381 370 751 450 339 789 360 320 1,469 9 -5 % Pharmaceutical Sales 3.0% 2.7% 2.9% 3.2% 2.7% 2.9% 2.8% 2.6% 2.8% Canada 141 127 268 189 166 354 166 158 678 -23 -24 % Pharmaceutical Sales 1.1% 0.9% 1.0% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% Other 152 179 329 87 94 182 105 126 414 90 81 % Pharmaceutical Sales 1.2% 1.6% 1.1% 0.6% 0.6% 0.7% 0.9% 1.0% 0.8% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 2Q23 2Q22 June YTD 2023 June YTD 2022 Interest income (109) $ (15) $ (221) $ (22) $ Interest expense 277 240 519 483 Exchange losses 62 86 122 124 Loss (income) from investments in equity securities, net (1) 175 284 (274) 991 Net periodic defined benefit plan (credit) cost other than service cost (111) (27) (226) (148) Other, net (122) (130) 339 (280) Total 172 $ 438 $ 259 $ 1,148 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 -- 9 of 9 --